Humankind Investments’s ImmunityBio IBRX Stock Holding History

Humankind Investments’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11,184	Closed	-$33.7K	–	155
2025 Q1	$33.7K	Buy	+11,184	New	+$33.9K	0.01%	147

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return

Humankind Investments's IBRX Position: Q2 2025 in Review

Humankind Investments sold out of ImmunityBio (IBRX) in Q2 2025, closing a stake of 11,184 shares — an estimated $33.7K sold.

Humankind Investments first reported a position in IBRX in Q1 2025 and held it in 1 quarter. The position peaked at $33.7K in Q1 2025. 241 funds tracked by Wall St. Rank hold IBRX as of Q2 2025.

Humankind Investments reported no remaining ImmunityBio position as of Q2 2025 after selling out during the quarter.
Humankind Investments sold 11,184 ImmunityBio shares in Q2 2025, an estimated $33.7K.
Humankind Investments first reported a position in ImmunityBio in Q1 2025 and held it in 1 quarter.
Humankind Investments's ImmunityBio position peaked at $33.7K in Q1 2025.
241 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2025.

Based on Humankind Investments's 13F filing for Q2 2025, filed 14 Aug 2025.